Lilly has entered into a collaboration and license agreement with Gate Bioscience to discover, develop, and commercialise molecular gate therapeutics. Through this deal, valued at up to US$856 M, Lilly will utilise Gate’s molecular gate drug discovery platform to identify molecular gates that can target and eliminate challenging proteins through novel mechanisms of action to address diseases with significant unmet medical needs. This deal marks the first publicly announced pharma partnership for Gate since it was founded in 2021.